GHRP-6: Research Overview and Mechanism

GHRP-6 is a synthetic six-residue peptide (His-D-Trp-Ala-Trp-D-Phe-Lys-NH2) that acts as an agonist of the growth hormone secretagogue receptor, GHS-R1a. Its molecular weight is near 873 g/mol.

As one of the earliest growth hormone-releasing peptides characterized, GHRP-6 is a foundational reference compound in secretagogue research and a frequent baseline for comparison against later analogs such as GHRP-2 and Hexarelin.

In laboratory and preclinical research, GHRP-6 is studied for GHS-R (ghrelin) receptor agonism, ghrelin signaling, growth hormone-secretion dynamics, and secretagogue pharmacology. As one of the first synthetic secretagogues characterized, it was central to the work that led to identification of the growth hormone secretagogue receptor itself, and it activates that Gq-coupled receptor in somatotrophs, which is why it remains a common baseline agonist against which later analogs such as GHRP-2 and Hexarelin are compared.

These are research applications and historical context reported in the literature, not human outcomes; GHRP-6 has not been approved for human use, and this product is supplied for research use only.

Pinnacle GHRP-6 is a lyophilized hexapeptide (molecular weight near 873 g/mol) with an unmodified tryptophan at the second position that sets it apart from the methylated Hexarelin; it is stored at -20C, protected from light, and reconstituted with bacteriostatic water for research use. As a foundational reference compound, each batch ships with a lot-matched Certificate of Analysis from independent HPLC and mass-spectrometry testing, so comparisons against later analogs start from a verified molecule.